

**Ivermectin / Pyrantel Formulation**

Version            Revision Date:            SDS Number:            Date of last issue: 04/24/2019  
7.1                09/13/2019                52652-00015            Date of first issue: 02/02/2015

---

**SECTION 1. IDENTIFICATION**

Product name                                : Ivermectin / Pyrantel Formulation

**Manufacturer or supplier's details**

Company name of supplier                : Merck & Co., Inc  
Address                                        : 2000 Galloping Hill Road  
    Kenilworth - New Jersey - U.S.A. 07033  
Telephone                                    : 908-740-4000  
Telefax                                        : 908-735-1496  
Emergency telephone                       : 1-908-423-6000  
E-mail address                               : EHSDATASTEWARD@merck.com

**Recommended use of the chemical and restrictions on use**

Recommended use                            : Veterinary product

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS classification in accordance with 29 CFR 1910.1200**

Combustible dust

**GHS label elements**

Signal Word                                 : Warning

Hazard Statements                         : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.

**Other hazards**

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.

---

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture                        : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)	22204-24-6	$\geq 5 - < 10$
Propylene glycol	57-55-6	$\geq 1 - < 5$
Ivermectin	70288-86-7	$< 0.1$

Actual concentration is withheld as a trade secret

---

**SECTION 4. FIRST AID MEASURES**

General advice                                : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

---

## Ivermectin / Pyrantel Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
7.1	09/13/2019	52652-00015	Date of first issue: 02/02/2015

---

If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	Wash with water and soap. Get medical attention if symptoms occur.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	:	No special precautions are necessary for first aid responders.
Notes to physician	:	Treat symptomatically and supportively.

---

### SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Nitrogen oxides (NO <sub>x</sub> ) Sulfur oxides Metal oxides Chlorine compounds
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

---

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	Follow safe handling advice and personal protective equipment recommendations.
Environmental precautions	:	Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages

## Ivermectin / Pyrantel Formulation

Version 7.1      Revision Date: 09/13/2019      SDS Number: 52652-00015      Date of last issue: 04/24/2019  
 Date of first issue: 02/02/2015

cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
 Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
 Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
 Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
 Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
 Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.  
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
 Minimize dust generation and accumulation.  
 Keep container closed when not in use.  
 Keep away from heat and sources of ignition.  
 Take precautionary measures against static discharges.  
 Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.  
 Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)	22204-24-6	TWA	10 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal
Propylene glycol	57-55-6	TWA	10 mg/m <sup>3</sup>	US WEEL
Ivermectin	70288-86-7	TWA	0.05 mg/m <sup>3</sup> (OEB)	Internal

## Ivermectin / Pyrantel Formulation

Version 7.1      Revision Date: 09/13/2019      SDS Number: 52652-00015      Date of last issue: 04/24/2019  
 Date of first issue: 02/02/2015

			3)	
	Further information: Skin			
		Wipe limit	0.5 mg/100 cm <sup>2</sup>	Internal

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
 Minimize open handling.

**Personal protective equipment**

**Respiratory protection** : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

**Hand protection**

**Material** : Chemical-resistant gloves

**Remarks** : Consider double gloving.

**Eye protection** : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**Ivermectin / Pyrantel Formulation**

Version            Revision Date:            SDS Number:            Date of last issue: 04/24/2019  
7.1                09/13/2019              52652-00015            Date of first issue: 02/02/2015

---

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance	:	powder
Color	:	brown
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	4 - 6 (68 °F / 20 °C) (as aqueous solution)
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	log Pow: 3.22
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive

**Ivermectin / Pyrantel Formulation**

Version            Revision Date:            SDS Number:            Date of last issue: 04/24/2019  
7.1                09/13/2019              52652-00015            Date of first issue: 02/02/2015

---

Oxidizing properties            :    The substance or mixture is not classified as oxidizing.  
  
Particle size                      :    No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity                        :    Not classified as a reactivity hazard.  
Chemical stability               :    Stable under normal conditions.  
Possibility of hazardous reac- :    May form explosive dust-air mixture during processing,  
tions                                :    handling or other means.  
   :    Can react with strong oxidizing agents.  
  
Conditions to avoid              :    Heat, flames and sparks.  
   :    Avoid dust formation.  
  
Incompatible materials         :    Oxidizing agents  
Hazardous decomposition      :    No hazardous decomposition products are known.  
products

---

**SECTION 11. TOXICOLOGICAL INFORMATION****Information on likely routes of exposure**

Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity              :    Acute toxicity estimate: > 5,000 mg/kg  
   :    Method: Calculation method

**Components:****4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

Acute oral toxicity              :    LD50 (Rat): > 24,000 mg/kg  
  
   :    LD50 (Mouse): > 24,000 mg/kg  
  
   :    LD50 (Dog): 2,000 mg/kg

**Propylene glycol:**

Acute oral toxicity              :    LD50 (Rat): > 5,000 mg/kg  
  
Acute inhalation toxicity       :    LC50 (Rabbit): > 159 mg/l  
   :    Exposure time: 4 h  
   :    Test atmosphere: dust/mist  
  
Acute dermal toxicity            :    LD50 (Rabbit): > 2,000 mg/kg  
   :    Assessment: The substance or mixture has no acute dermal  
   :    toxicity

---

## Ivermectin / Pyrantel Formulation

Version 7.1	Revision Date: 09/13/2019	SDS Number: 52652-00015	Date of last issue: 04/24/2019 Date of first issue: 02/02/2015
----------------	------------------------------	----------------------------	---

---

**Ivermectin:**

Acute oral toxicity : LD50 (Rat): 50 mg/kg  
LD50 (Mouse): 25 mg/kg  
LD50 (Monkey): > 24 mg/kg  
Target Organs: Central nervous system  
Symptoms: Vomiting, Dilatation of the pupil  
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5.11 mg/l  
Exposure time: 1 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg  
LD50 (Rat): > 660 mg/kg

**Skin corrosion/irritation**

Not classified based on available information.

**Components:**

**Propylene glycol:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

**Ivermectin:**

Species : Rabbit  
Result : No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:**

**Propylene glycol:**

Species : Rabbit  
Result : No eye irritation  
Method : OECD Test Guideline 405

**Ivermectin:**

Species : Rabbit  
Result : Mild eye irritation

**Respiratory or skin sensitization**

**Skin sensitization**

Not classified based on available information.

**Ivermectin / Pyrantel Formulation**

Version            Revision Date:            SDS Number:            Date of last issue: 04/24/2019  
7.1                09/13/2019              52652-00015            Date of first issue: 02/02/2015

---

**Respiratory sensitization**

Not classified based on available information.

**Components:****Propylene glycol:**

Test Type                                : Maximization Test  
Routes of exposure                    : Skin contact  
Species                                    : Guinea pig  
Result                                      : negative

**Ivermectin:**

Routes of exposure                    : Dermal  
Species                                    : Humans  
Result                                      : Does not cause skin sensitization.

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

Genotoxicity in vitro                : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

**Propylene glycol:**

Genotoxicity in vitro                : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Genotoxicity in vivo                : Test Type: Mammalian erythrocyte micronucleus test (in vivo  
cytogenetic assay)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

**Ivermectin:**

Genotoxicity in vitro                : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-  
thesis in mammalian cells (in vitro)  
Test system: human diploid fibroblasts  
Result: negative

Test Type: Mouse Lymphoma  
Result: negative

**Carcinogenicity**

Not classified based on available information.



## Ivermectin / Pyrantel Formulation

Version 7.1      Revision Date: 09/13/2019      SDS Number: 52652-00015      Date of last issue: 04/24/2019  
 Date of first issue: 02/02/2015

---

**Components:****Propylene glycol:**

Species : Rat  
 Application Route : Ingestion  
 Exposure time : 2 Years  
 Result : negative

**Ivermectin:**

Species : Rat  
 Application Route : Oral  
 NOAEL : 1.5 mg/kg body weight  
 Result : negative  
 Remarks : Based on data from similar materials

Species : Mouse  
 Application Route : Oral  
 NOAEL : 2.0 mg/kg body weight  
 Result : negative  
 Remarks : Based on data from similar materials

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

**Reproductive toxicity**

Not classified based on available information.

**Components:****4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

Effects on fetal development : Test Type: Embryo-fetal development  
 Species: Rat  
 Application Route: Oral  
 Developmental Toxicity: NOAEL: 3,000 mg/kg body weight  
 Result: No effects on fertility and early embryonic development were detected.

Test Type: Embryo-fetal development  
 Species: Rabbit  
 Application Route: Oral  
 Developmental Toxicity: NOAEL: 1,000 mg/kg body weight  
 Result: No effects on fertility and early embryonic development were detected.

**Propylene glycol:**

Effects on fertility : Test Type: Three-generation reproduction toxicity study

**Ivermectin / Pyrantel Formulation**

Version      Revision Date:      SDS Number:      Date of last issue: 04/24/2019  
7.1          09/13/2019          52652-00015      Date of first issue: 02/02/2015

---

Species: Mouse  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Ivermectin:**

Effects on fertility : Test Type: Fertility  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 0.6 mg/kg body weight  
Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development  
Species: Mouse  
Application Route: Oral  
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight  
Result: Teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL: 0.4 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected.  
Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Result: Teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

**STOT-single exposure**

Not classified based on available information.

**Components:****Ivermectin:**

Target Organs : Central nervous system  
Assessment : Causes damage to organs.

**STOT-repeated exposure**

Not classified based on available information.

## Ivermectin / Pyrantel Formulation

Version 7.1      Revision Date: 09/13/2019      SDS Number: 52652-00015      Date of last issue: 04/24/2019  
 Date of first issue: 02/02/2015

---

### Components:

#### **Ivermectin:**

Target Organs : Central nervous system  
 Assessment : Causes damage to organs through prolonged or repeated exposure.

### **Repeated dose toxicity**

#### Components:

#### **4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

Species : Dog  
 NOAEL : 10 mg/kg  
 LOAEL : 30 mg/kg  
 Application Route : Ingestion  
 Exposure time : 3 d  
 Remarks : No significant adverse effects were reported

Species : Dog  
 NOAEL : 600 mg/kg  
 Application Route : Oral  
 Exposure time : 19 d  
 Remarks : No significant adverse effects were reported

Species : Dog  
 NOAEL : 600 mg/kg  
 Application Route : Oral  
 Exposure time : 30 d  
 Remarks : No significant adverse effects were reported

Species : Dog  
 NOAEL : 600 mg/kg  
 Application Route : Oral  
 Exposure time : 90 d  
 Remarks : No significant adverse effects were reported

#### **Propylene glycol:**

Species : Rat, male  
 NOAEL : 1,700 mg/kg  
 Application Route : Ingestion  
 Exposure time : 2 y

#### **Ivermectin:**

Species : Dog  
 NOAEL : 0.5 mg/kg  
 LOAEL : 1 mg/kg  
 Application Route : Oral  
 Exposure time : 14 Weeks  
 Target Organs : Central nervous system  
 Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

## Ivermectin / Pyrantel Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
7.1	09/13/2019	52652-00015	Date of first issue: 02/02/2015

Species	:	Monkey
NOAEL	:	1.2 mg/kg
Application Route	:	Oral
Exposure time	:	2 Weeks
Remarks	:	No significant adverse effects were reported

Species	:	Rat
NOAEL	:	0.4 mg/kg
LOAEL	:	0.8 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	spleen, Bone marrow, Kidney

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

#### **4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

Ingestion	:	Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhea, Headache, Dizziness, Fever
-----------	---	--

#### **Ivermectin:**

Skin contact	:	Remarks: Can be absorbed through skin.
Eye contact	:	Remarks: May irritate eyes.
Ingestion	:	Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Product:

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l Exposure time: 96 h
	:	LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0.000025 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
	:	NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l Exposure time: 72 h Method: OECD Test Guideline 201

## Ivermectin / Pyrantel Formulation

Version            Revision Date:            SDS Number:            Date of last issue: 04/24/2019  
7.1                    09/13/2019                52652-00015            Date of first issue: 02/02/2015

**Components:**

**4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**

**Ecotoxicology Assessment**

Acute aquatic toxicity            : Toxic effects cannot be excluded

Chronic aquatic toxicity        : Toxic effects cannot be excluded

**Propylene glycol:**

Toxicity to fish                    : LC50 (Oncorhynchus mykiss (rainbow trout)): 40,613 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other    : EC50 (Ceriodaphnia dubia (water flea)): 18,340 mg/l  
aquatic invertebrates            Exposure time: 48 h

Toxicity to algae/aquatic        : ErC50 (Skeletonema costatum (marine diatom)): 19,300 mg/l  
plants                                Exposure time: 72 h  
Method: OECD Test Guideline 201

Toxicity to daphnia and other    : NOEC (Ceriodaphnia dubia (water flea)): 13,020 mg/l  
aquatic invertebrates (Chron-    Exposure time: 7 d  
ic toxicity)

Toxicity to microorganisms      : NOEC (Pseudomonas putida): > 20,000 mg/l  
Exposure time: 18 h

**Ivermectin:**

Toxicity to fish                    : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l  
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other    : EC50 (Daphnia magna (Water flea)): 0.000025 mg/l  
aquatic invertebrates            Exposure time: 48 h

Toxicity to algae/aquatic        : EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1  
plants                                mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1  
mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

**Persistence and degradability****Product:**

Biodegradability                 : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 240 d

**Ivermectin / Pyrantel Formulation**

Version 7.1      Revision Date: 09/13/2019      SDS Number: 52652-00015      Date of last issue: 04/24/2019  
Date of first issue: 02/02/2015

---

**Components:****Propylene glycol:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 98.3 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301F

**Ivermectin:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 240 d

**Bioaccumulative potential****Product:**

Bioaccumulation : Bioconcentration factor (BCF): 74

**Components:****Propylene glycol:**

Partition coefficient: n-octanol/water : log Pow: -1.07

**Ivermectin:**

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-octanol/water : log Pow: 3.22

**Mobility in soil**

No data available

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.

---

## Ivermectin / Pyrantel Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
7.1	09/13/2019	52652-00015	Date of first issue: 02/02/2015

---

(Ivermectin)

Class : 9  
 Packing group : III  
 Labels : 9

### IATA-DGR

UN/ID No. : UN 3077  
 Proper shipping name : Environmentally hazardous substance, solid, n.o.s.  
 (Ivermectin)

Class : 9  
 Packing group : III  
 Labels : Miscellaneous  
 Packing instruction (cargo aircraft) : 956  
 Packing instruction (passenger aircraft) : 956  
 Environmentally hazardous : yes

### IMDG-Code

UN number : UN 3077  
 Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,  
 N.O.S.  
 (Ivermectin)

Class : 9  
 Packing group : III  
 Labels : 9  
 EmS Code : F-A, S-F  
 Marine pollutant : yes

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### Domestic regulation

#### 49 CFR

UN/ID/NA number : UN 3077  
 Proper shipping name : Environmentally hazardous substance, solid, n.o.s.  
 (Ivermectin)

Class : 9  
 Packing group : III  
 Labels : CLASS 9  
 ERG Code : 171  
 Marine pollutant : yes(Ivermectin)  
 Remarks : Above applies only to containers over 119 gallons or 450 liters., Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

## Ivermectin / Pyrantel Formulation

Version      Revision Date:      SDS Number:      Date of last issue: 04/24/2019  
 7.1          09/13/2019          52652-00015      Date of first issue: 02/02/2015

### SECTION 15. REGULATORY INFORMATION

#### EPCRA - Emergency Planning and Community Right-to-Know

##### CERCLA Reportable Quantity

Components	CAS-No.	Component RQ (lbs)	Calculated product RQ (lbs)
Potassium hydroxide	1310-58-3	1000	*
Acetic acid	64-19-7	5000	*

\*: Calculated RQ exceeds reasonably attainable upper limit.

##### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

##### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards**      :    Combustible dust

**SARA 313**                        :    This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

#### US State Regulations

##### Pennsylvania Right To Know

Soybean proteins	9010-10-0
4,4'-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)	22204-24-6
D(+)-Glucose monohydrate	5996-10-1
Propylene glycol	57-55-6
D-Glucono-1,5-lactone	90-80-2

##### California Prop. 65

WARNING: This product can expose you to chemicals including tert-Butyl-4-methoxyphenol, which is/are known to the State of California to cause cancer. For more information go to [www.P65Warnings.ca.gov](http://www.P65Warnings.ca.gov).


##### The ingredients of this product are reported in the following inventories:

AICS                                :    not determined  
 DSL                                 :    not determined  
 IECSC                             :    not determined



## Ivermectin / Pyrantel Formulation

Version 7.1      Revision Date: 09/13/2019      SDS Number: 52652-00015      Date of last issue: 04/24/2019  
 Date of first issue: 02/02/2015

**SECTION 16. OTHER INFORMATION****Further information****NFPA 704:****HMIS® IV:**

<b>HEALTH</b>	/	0
<b>FLAMMABILITY</b>		3
<b>PHYSICAL HAZARD</b>		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

**Full text of other abbreviations**

US WEEL : USA. Workplace Environmental Exposure Levels (WEEL)  
 US WEEL / TWA : 8-hr TWA

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance

## Ivermectin / Pyrantel Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
7.1	09/13/2019	52652-00015	Date of first issue: 02/02/2015

---

Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 09/13/2019

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8